SCHEMBL14306

SCHEMBL14306

NCc1ccc(-n2cc3cc(-c4cc(F)c(C(=O)NC5CCNCC5)c(F)c4)[nH]c3nc2=O)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 5/20 0.38
CCNA2 P20248 4/20 0.38
CCNA1 P78396 2/20 0.38
CDK1 P06493 1/20 0.38
CCNB1 P14635 1/20 0.38
WNT1 P04628 1/20 0.36
DYRK1A Q13627 1/20 0.36
AKT1 P31749 1/20 0.36
PARP1 P09874 3/20 0.35
KDM1A O60341 1/20 0.34
SUV39H1 O43463 1/20 0.33
PRMT1 Q99873 1/20 0.33
SMYD3 Q9H7B4 1/20 0.33
TNK2 Q07912 1/20 0.33
TNK1 Q13470 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
ACKR3 P25106 1/20 0.33
BMPR1B O00238 1/20 0.33
BMPR1A P36894 1/20 0.33
TGFBR1 P36897 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14513 0.87 RIPK1 (0.46) SUV39H1PRMT1SMYD3KHKRIPK1
SCHEMBL14512 0.79 RIPK1 (0.41) SMYD3KHKRIPK1NTRK1DHODH
SCHEMBL13865 0.78 RIPK1 (0.40) SMYD3KHKRIPK1NTRK1DHODH
SCHEMBL14303 0.78 HDAC4 (0.37) CDK2CCNA2AKT1PARP1KDM1A
SCHEMBL13856 0.73 KLKB1 (0.38) SMYD3ACKR3BMPR1BBMPR1ATGFBR1
SCHEMBL14232 0.73 RIPK1 (0.39) KDM1ASMYD3KHKRIPK1DHODH
SCHEMBL14057 0.73 RIPK1 (0.36) KDM1ASMYD3KHKRIPK1DHODH
SCHEMBL14330 0.73 RIPK1 (0.38) KDM1ASMYD3KHKRIPK1DHODH
SCHEMBL14436 0.72 RIPK1 (0.39) SMYD3KHKRIPK1DHODH
SCHEMBL14517 0.72 CHRM3 (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2488525-B1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME MELINTA THERAPEUTICS INC (US) 2018-04-25 EP disclosed
US-20160031893-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME BioVersys AG (CH) 2016-02-04 US disclosed
US-9193731-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2015-11-24 US disclosed
US-9193731-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2015-11-24 US disclosed
US-20120220566-A1 Antimicrobial Compounds and Methods of Making and Using the Same RIB-X PHARMACEUTICALS, INC. (US) 2012-08-30 US disclosed
US-20120220566-A1 Antimicrobial Compounds and Methods of Making and Using the Same RIB-X PHARMACEUTICALS, INC. (US) 2012-08-30 US disclosed
WO-2011047319-A2 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME RIB-X PHARMACEUTICALS, INC. (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220566-A1 Antimicrobial Compounds and Methods of Making and Using the Same MPO, LPO, CAT CDK2 4787/4885CCNA2 4473/4885CCNA1 4311/4885
US-20160031893-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME MPO, LPO, CAT CDK2 4787/4885CCNA2 4473/4885CCNA1 4311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.